Year: 2019

Paris, France and Camberley, UK – 19 June 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 23 April 2019, it has issued a tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma Group

Paris, France et Camberley, UK – 14 juin 2019 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT) annonce qu’en vertu du programme de financement par des Obligations Convertibles assorties de warrants annoncé le 23 avril 2019, elle a émis deux tranches d’actions ordinaires nouvelles de 1/15ème d’euro chacune (« Actions Ordinaires ») à Negma Group

Paris, France and Camberley, UK – 14 June 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 23 April 2019, it has issued a tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma Group

Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers http://novacyt.com/wp-content/uploads/2019/06/NOVACYT_CP_Droits-de-vote_2019-Juin.pdf

Paris, France and Camberley, UK – 3 June 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further summarised

Paris, France et Camberley, Royaume-Uni – 24 mai 2019 – Novacyt (EURONEXT GROWTH : ALNOV ; AIM : NCYT), spécialiste international du diagnostic clinique, annonce aujourd’hui la publication du rapport annuel du Groupe pour l’exercice clos le 31 décembre 2018, disponible sur le site Internet du Groupe. La version imprimée du rapport annuel sera également

Paris, France and Camberley, UK – 24 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces that the Company’s Annual Report and Accounts (“Annual Report”) for the year ended 31 December 2018 has been published and uploaded to the Company’s website. The Annual Report will also be

Paris, France and Camberley, UK – 17 May 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT) an international specialist in clinical diagnostics, announces that, pursuant to the Convertible Bonds with Warrants Funding Programme announced on 23 April 2019, it has issued a tranche of new ordinary shares of €1/15 each (“Ordinary Shares”) to Negma Group

Paris, France et Camberley, UK – 17 mai 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic Clinique, annonce qu’en vertu du Programme de Financement par Obligations Convertibles assorties de Warrants annoncé le 23 avril 2019, elle a émis une tranche d’actions ordinaires nouvelles de 1/15 € chacune (« Actions Ordinaires ») à Negma Group

Paris, France et Camberley, UK – 15 mai 2019 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), spécialiste international du diagnostic Clinique, annonce qu’en vertu du Programme de Financement par Obligations Convertibles assorties de Warrants (“l’Accord”) annoncé le 23 avril 2019, elle a émis une tranche d’actions ordinaires nouvelles de 1/15 € chacune (“Actions Ordinaires”) à Negma